X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Filspari (sparsentan) is a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It isapproved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
Filspari (sparsentan) is a once-daily oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It is approved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Filspari (sparsentan) is a once-daily oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It is approved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Under the agreement, Renalys will bring Filspari (sparsentan), a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Renalys Pharma
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 25, 2024
Details:
Filspari (sparsentan) is a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It isapproved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Filspari (sparsentan), a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II), and is the first and only non-immunosuppressive therapy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 03, 2023
Details:
Filspari (sparsentan), a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II), and is the first and only non-immunosuppressive therapy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
RE-021 (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R).
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R).
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
After 36 weeks of treatment, patients receiving RE-021 (sparsentan) achieved a mean reduction in proteinuria from baseline of 49.8 percent, compared to a mean reduction in proteinuria from baseline of 15.1 percent for irbesartan-treated patients.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Travere Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
RE-021 (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R).
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
RE-021 (sparsentan), a dual endothelin angiotensin receptor antagonist (DEARA), and a novel investigational product candidate selectively targeting the endothelin A receptor and the angiotensin II subtype 1 receptor, in IgA nephropathy and focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
The PROTECT Study evaluating RE-021 (sparsentan) in 404 patients with persistent proteinuria, met its pre-specified interim primary efficacy endpoint measuring change in proteinuria compared to the active control irbesartan.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
NDA submission is supported by positive result from PROTECT Study, evaluating safety and efficacy of sparsentan, a DEAR antagonist in a total of 404 patients with IgAN, as well as data from additional clinical trials and pre-clinical testing of sparsentan.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Sparsentan data shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, reduces proteinuria, protects podocytes and prevents glomerulosclerosis and mesangial cell proliferation.
Lead Product(s): Sparsentan
Therapeutic Area: Immunology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
Under the terms of the agreement, Vifor Pharma will receive exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand and Travere remains responsible for the clinical development of sparsentan and will retain all rights to sparsentan.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: $190.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration September 16, 2021
Details:
Preliminary results from the interim analysis suggest that to date in the study, sparsentan has been generally well-tolerated and consistent with the observed safety profile to date.
Lead Product(s): Sparsentan
Therapeutic Area: Immunology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Preliminary results from the interim analysis suggest that at the time of the interim assessment, sparsentan had been generally well-tolerated and shown a comparable safety profile to irbesartan.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.
Lead Product(s): Sparsentan
Therapeutic Area: Immunology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
Retrophin will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology Kidney Week 2020 Reimagined.
Lead Product(s): Sparsentan
Therapeutic Area: Immunology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
First 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN).
Lead Product(s): Sparsentan
Therapeutic Area: Immunology Product Name: RE-021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
